OTCMKTS : $OCEL 📋 Organicell Activates COPD Trial at Mayo Clinic! | News Direct

OTCMKTS : $OCEL 📋 Organicell Activates COPD Trial at Mayo Clinic! Benzinga Digital Content Studio

Digital Asset Direct by Organicell Regenerative Medicine, Inc.

facebook icon linkedin icon twitter icon pinterest icon email icon Detroit, Michigan | November 16, 2022 01:20 PM Eastern Standard Time

Phase I/II clinical trials will be held at Mayo Clinic in Phoenix, Arizona to study the safety and efficacy of Organicell Regenerative Medicine, Inc.'s (OTCMKTS: OCEL) drug, Zofin, in benefiting sufferers of Chronic Obstructive Pulmonary Disease (COPD)! 🗒 Organicell Regenerative Medicine, Inc., is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases & the provision of other related services. Visit Organicell here 👉 https://organicell.com/


Contact Details


Organicell Investor Relations




Company Website